Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Zacks.com on MSN2d
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesGSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...
GlobalData on MSN3d
MHLW accepts GSK’s multiple myeloma treatment NDA for reviewThe NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback